Crossbow Therapeutics Nominates its Second Development Candidate, CBX-663, a Broadly Acting Therapeutic for a Wide Range of Solid and Hematologic Malignancies
CBX-663, a bispecific antibody, binds to TERT-derived peptide human leukocyte antigen (pHLA) complexes on the surface of tumor cells and activates T-cells through a CD3-binding arm. The molecule includes two binding domains for TERT, which increase its ability to engage tumor cells and boost immune activation.
'CBX-663 illustrates how Crossbow's TCR-mimetic platform can unlock new opportunities for antibody-based cancer therapies,' said Briggs Morrison, MD, Chief Executive Officer of Crossbow. 'With strong preclinical performance selectively targeting a pHLA expressed across a broad range of cancers, CBX-663 has the potential to offer a meaningful new treatment option for patients with limited therapeutic options.'
In preclinical studies, CBX-663 drove potent, antigen-specific tumor killing across multiple TERT-positive cancer models, with minimal activity against TERT-negative or HLA-mismatched cells. The candidate also demonstrated a favorable safety profile and pharmacokinetics comparable to conventional antibody therapies. Crossbow presented data summarizing the initial characterization of CBX-663 at the 2025 Annual Meeting of the American Association for Cancer Research (AACR).
Although TERT resides inside the cell, HLA molecules can present fragments of the protein, known as peptides, on the tumor surface. CBX-663 recognizes one of those peptides, the HLA-A*02:01-restricted TERT540 peptide, and redirects T-cells to attack tumor cells. CBX-663 demonstrated broad cytotoxic activity in vitro in both solid and hematologic cancer cell lines, as well as in primary patient samples ex vivo. In vivo studies further confirmed its anti-tumor efficacy and tolerability.
'CBX-663 reflects the depth of antibody discovery and protein engineering that underpins our T-Bolt™ platform and our ability to generate highly selective, potent molecules against difficult cancer targets,' said Dmitri Wiederschain, PhD, Chief Scientific Officer of Crossbow. 'Its performance in preclinical models reinforces the promise of TCR-mimetic therapeutics, and we're excited to continue advancing this program.'
Crossbow discovered and developed CBX-663 through its proprietary T-Bolt™ platform, which uses optimized antibody libraries and precision screening to find high-affinity, specific binders to intracellular tumor antigens displayed as pHLA complexes.
The nomination of CBX-663 underscores the platform's potential to deliver a scalable pipeline of T-cell engagers for difficult-to-treat cancers.
About Crossbow Therapeutics, Inc.
Crossbow Therapeutics, Inc., is a biotechnology company determined to improve the lives of people with cancer by unlocking the therapeutic potential of T-cell receptor (TCR)-mimetic antibodies. The company's T-Bolt™ therapies are next-generation, easily assembled immunotherapies directed with high precision at previously unreachable cancer cell targets. Crossbow's efficient and selective approach is designed to target the entire universe of cancer proteins, dramatically expanding the potential of antibody therapy to address many types of cancer. For more information about Crossbow Therapeutics, visit www.crossbowtx.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
9 minutes ago
- Business Wire
Reddit Accelerates Innovation and Slashes Build Times with Buildkite
SAN FRANCISCO--(BUSINESS WIRE)-- Buildkite Pty Ltd., a leader in scalable software delivery solutions, today announced that Reddit, one of the world's largest online communities with more than over 400M weekly active users, has successfully migrated its mobile continuous integration and delivery (CI/CD) pipelines to Buildkite, dramatically improving build performance, reliability, and developer autonomy across its mobile engineering organization. By adopting Buildkite's high-performance hosted agents and dynamic pipeline primitives, Reddit has reduced build queue times to just seconds and accelerated build speeds by 30% for both Android and iOS workflows, while maintaining cost efficiency. By adopting Buildkite's high-performance hosted agents and dynamic pipeline primitives, Reddit has reduced build queue times to just seconds and accelerated build speeds by 30% for both Android and iOS workflows, while maintaining cost efficiency. Share 'With Buildkite, we finally have the reliability and performance at scale that our mobile teams were missing,' said Ken Struys, Reddit's Director of Developer Experience. 'We've seen a significant improvement to the overall developer experience, and both Android and iOS CI are more than 30% faster on Buildkite.' Facing growing demands from millions of global users and a rapidly expanding codebase, Reddit's mobile teams had outgrown their previous CI/CD provider. Lack of ability to control the build environment meant they couldn't use custom Docker images (as they can with Buildkite). The team also struggled with configuration complexity, with 6,000 lines of YAML split across multiple files, in addition to unreliable builds due to environment drift and dependency failures. Reddit's migration to Buildkite, affecting over 200 mobile engineers, was completed ahead of schedule and involved a full transition of both Android and iOS mono repositories. The company leveraged Buildkite's composable pipeline primitives to create custom workflows that seamlessly integrated with Bazel and BuildBuddy, allowing both iOS and Android apps to be built efficiently on Linux runners with remote execution. Dynamic pipelines enabled Reddit to build powerful CI systems with less cruft and less code repetition. Comprehensive benchmarking revealed that Reddit's builds now run up to 30% faster, with job queue times consistently dropping to around five seconds. Buildkite's Git caching and container caching features were 'absolute game changers,' reducing Git checkout times from several minutes to 30-40 seconds. Intelligent build cancellation and log customization further improved developer experience and operational efficiency. The migration was conducted by a remarkably lean core team. 'We built most of the Android pipelines and the iOS pipelines with two people,' said Struys. 'You don't need massive engineering resources to use Buildkite, but the scale is tremendous. We've got 170 plus engineers on it now, and most of our builds are running like 12 to 15 jobs in each field now.' It was also executed with exceptional care through a staged approach, including having shadow builds running in parallel to production systems to ensure a zero-risk transition. Buildkite's team provided responsive support and delivered custom feature requests, including a GitHub App for GitHub Enterprise Server, throughout the process. "Reddit's successful migration exemplifies the transformative power of modern, composable CI/CD architecture," said Dan Ring, Vice President of Product at Buildkite, who worked closely with the company on the migration. "When engineering organizations outgrow traditional CI/CD limitations, they need a platform that can deliver both immediate performance gains and long-term scalability. Reddit's experience demonstrates what's possible when you combine Buildkite's high-performance hosted agents with our flexible, composable primitives. This isn't just about faster builds, it's about unleashing engineering teams to innovate at the speed their users demand." For more information, see Reddit's blog post here. About Buildkite Pty Ltd: Based in San Francisco and Melbourne, Buildkite is a fast-growing software delivery provider that offers the industry's first and only Scale-Out Delivery Platform. Buildkite's Scale-Out Delivery platform is the only solution that provides the flexibility and scale required by the world's most demanding companies for delivering software across a broad range of use cases, including AI/ML workloads and mobile application development. Global innovation leaders including Airbnb, Block, Canva, Cruise, Culture Amp, Elastic, Lyft, PagerDuty, Pinterest, PlanetScale, Rippling, Shopify, Slack, Tinder, Twilio, Uber, and Wayfair have standardized on Buildkite for software delivery. For more information, please visit
Business Wire
9 minutes ago
- Business Wire
Mortgage Rates Drop to Lowest Level in 10 Months, Upping Purchasing Power in a Buyer-Friendly Market
SEATTLE--(BUSINESS WIRE)--The daily average mortgage rate dropped to 6.57% on August 4, the lowest level in 10 months, according to a new report from Redfin, the real estate brokerage powered by Rocket. That means a homebuyer on a $3,000 monthly budget has gained roughly $20,000 in purchasing power since May, when the daily average rate hit a recent peak of 7.08%. A buyer on that budget can afford a $458,750 home with today's mortgage rate, compared to the $439,000 home they could have bought with May's peak. To look at affordability another way, the monthly mortgage payment on the median-priced U.S. home, which goes for roughly $447,000, is $2,862 with today's average rate. In mid-May, when rates were sitting above 7%, the monthly payment would have been $2,983, over $100 more. Mortgage rates fell over the weekend following a weaker-than-expected July jobs report. The U.S. added fewer jobs than anticipated, and the unemployment rate ticked up, which pushed up the chances of the Fed cutting interest rates in September. 'This dip in mortgage rates gives house hunters a window of opportunity to buy before summer ends,' said Daryl Fairweather, Redfin's chief economist. 'While housing costs are still fairly high, the recent decline in rates boosts purchasing power and improves overall homebuying conditions. Combined with the surplus of homes for sale on the market, serious buyers may want to jump in sooner rather than later.' House hunters should take note that there are hundreds of thousands more home sellers than buyers in the market, giving many prospective buyers an opportunity to negotiate home prices down and ask for concessions. But the gap between sellers and buyers is starting to shrink as new listings decline, with would-be sellers opting to stay put instead of listing their home in a buyer's market. To view the full report, including a chart, please visit: About Redfin Redfin is a technology-driven real estate company with the country's most-visited real estate brokerage website. As part of Rocket Companies (NYSE: RKT), Redfin is creating an integrated homeownership platform from search to close to make the dream of homeownership more affordable and accessible for everyone. Redfin's clients can see homes first with on-demand tours, easily apply for a home loan with Rocket Mortgage, and save thousands in fees while working with a top local agent. You can find more information about Redfin and get the latest housing market data and research at For more information about Rocket Companies, visit
Business Upturn
10 minutes ago
- Business Upturn
Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Trial, Expanding its Coronary Clinical Program Across the U.S. and Europe
Concept Medical announces first patient enrollment in MAGICAL-SV IDE trial, expanding its Coronary Clinical Program across the U.S. and Europe. Business Wire India Concept Medical Inc. , a global pioneer in drug-delivery technologies, announced the enrollment of the first patient in the MAGICAL-SV (MAGIcTouch™ Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels) trial, a U.S. Investigational Device Exemption (IDE) study evaluating its MagicTouch™ sirolimus-coated balloon (SCB) for the treatment of small coronary vessels. This first U.S. enrollment follows the FDA's IDE approval of MagicTouch SCB, marking a major milestone in Concept Medical's mission to revolutionize coronary artery disease (CAD) treatment and expand its clinical program into the US and Europe. Dr. Samin Sharma enrolled the first patient at New York's Mount Sinai Hospital, Director of Interventional Cardiology, marking a crucial step in advancing treatment options for patients with small-vessel coronary artery disease. 'Today marks a great feat for us and for the MAGICAL-SV trial,' said Dr. Samin Sharma. 'My team at Mount Sinai is privileged to be the first to begin this study. This is a proud moment for all of us, especially knowing what the trial signifies and aims to achieve by evaluating MagicTouch as a potential alternative for treating small vessels in the U.S.' Concept Medical is now actively enrolling in three IDE trials concurrently in the U.S., across coronary and peripheral interventions, underscoring its commitment to bringing innovative therapies to patients worldwide. MAGICAL-SV is a prospective, multicenter, single-blind randomized trial (2:1 randomization) comparing Concept Medical's MagicTouch sirolimus-coated balloon to DES (Everolimus eluting stents [EES] or Zotarolimus eluting stents [ZES]) for the treatment of small coronary artery lesions. Randomization is stratified by study site and presence of medically-treated diabetes mellitus status. The trial will enroll 1,605 patients across the U.S. and Europe, to evaluate the primary endpoint of target lesion failure (TLF) at 12 months. An international team of renowned cardiologists, Dr. Martin B. Leon (USA) – Study Chair, with principal investigators (PI) Dr. Azeem Latib (USA), Dr. Ajay Kirtane (USA), and Prof. Antonio Colombo (Europe) will lead the MAGICAL-SV trial. Dr. Azeem Latib, a U.S. PI for MAGICAL-SV, noted, 'The first U.S. patient enrollment in the MAGICAL-SV study marks an exciting step forward in building robust evidence for SCB technology in the treatment of small-vessel coronary disease. As we explore metal-free PCI strategies, this study brings renewed hope for safer, more effective options for our patients.' Prof. Antonio Colombo, who leads the European arm, added, 'Starting small and going big! MAGICAL-SV represents an important step in building evidence for sirolimus-coated balloons.' This milestone embodies a 'leave nothing behind' philosophy in coronary interventions, treating arterial blockages without permanent implants and addressing the limitations of metallic stents in small vessels. Dr. Martin B. Leon, the Study Chair, emphasized evaluating a no-stent strategy through this trial: 'The initiation of the MAGICAL-SV trial marks an important step in evaluating sirolimus-coated balloon therapy for small coronary vessels. By addressing key limitations of stenting in this complex anatomy, the study aims to generate strong comparative data versus DES. The results could inform future treatment strategies in the U.S. and Europe, offering clinicians a potential alternative for managing small-vessel disease.' The pioneering MAGICAL-SV trial aims to yield strong clinical evidence for sirolimus-coated balloon therapy, supporting Pre-Market Approval (PMA) for MagicTouch SCB in small vessels and potentially redefining CAD treatment. Dr. Manish Doshi, Founder and MD of Concept Medical, said, "MAGICAL-SV marks another step in our mission to redefine vascular care. We're focused on delivering next-generation solutions, helping clinicians achieve better outcomes and give CAD patients a better quality of life." For media inquiries contact: [email protected] Disclaimer: The above press release comes to you under an arrangement with Business Wire India. Business Upturn take no editorial responsibility for the same. Ahmedabad Plane Crash
